VALUE-BASED DECISION MAKING IN DEVELOPING COUNTRIES- MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR OFF-PATENT PHARMACEUTICALS

Author(s)

Zoltan Kalo, PhD , Professor of Health Economics, Eötvös Loránd University (ELTE), 2) Syreon Research Institute, Budapest, Hungary; Anke-Peggy Holtorf, PhD, MBA , Managing Director, Health Outcomes Strategies, GmbH, Basel, Switzerland; Nikos Maniadakis,, Professor , Director, Alternate Dean, Department of Health Services Organization & Management, National School of Public Health,, Athens, Greece; Diana Brixner, PhD, RPh, FAMCP , Professor, Department of Pharmacotherapy, University of Utah College of Pharmacy,, Executive Director, Pharmacotherapy Outcomes Research Center, and Director of Outcomes,, University of Utah,, Salt Lake City,, USA; Kalman Emry Wijaya, PharmD., MBA , Global Market Access and Policy Sr. Manager, Global Market Access, Abbott Products Operations AG, Allschwil, Switzerland

Presentation Documents

ISPOR_Asia_Draft_v3_20180910

Developing countries often have challenges managing healthcare budgets without compromising effectiveness and safety of pharmaceuticals. In this session, value-based decision making for off-patent products and adaptation experiences in different developing countries (Indonesia, Vietnam, Kazakhstan, and Kuwait) will be discussed.

Conference/Value in Health Info

2018-09, ISPOR Asia Pacific 2018, Tokyo, Japan

Code

Topic

Health Technology Assessment, Specialized Treatment Areas

Explore Related HEOR by Topic

Presentation